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doi:10.1016/j.ejvs.2009.09.028Abstract Objectives: To evaluate the longterm outcome of venous thrombectomy and simul-
taneous stenting in patients with acute, symptomatic iliofemoral deep venous thrombosis
(DVT).
Methods: Between January 1996 and December 2007, a total of 45 patients underwent venous
thrombectomy at our institution. Thrombectomy results were classified by intraoperative phle-
bography as: TYPE IZ complete, TYPE IIZ partial, TYPE IIIZ complete with stenosis other
than thrombus, TYPE IVZ permanent occlusion. TYPEs I and IV were excluded from this anal-
ysis because no endovascular repair was performed.
25 patients underwent a venous hybrid operation comprising balloon-catheter thrombect-
omy, thrombolysis and stenting of residual stensosis. Three TYPE 2 and 22 TYPE 3 lesions were
diagnosed. Three patients died during follow-up from causes unrelated to their treatment.
Three were lost to follow-up. Hence, 19 patients were examined. A retrospective, non compar-
ative single-centre study was performed.
Results: Median follow-up was 68 months (range 3e129). Primary and secondary patency rates
were 74% (14/19) and 84% (16/19), respectively. Re-thrombosis occurred within seven days
of operation in 26% (5/19). Procedure related mortality was zero. There was no case of late
re-thrombosis. Four patients showed post-thrombotic sequelae (CEAP: C1, 2 or 3 s). No leg
ulcer developed in any patient.
Conclusion: Venous thrombectomy with simultaneous stenting results in excellent longterm
results in selected patients with symptomatic iliofemoral venous thrombosis.
ª 2009 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.21 566249; fax: þ49 6221 565423.
d.uni-heidelberg.de (P. Ho¨lper).
lsevier Ltd on behalf of European Society for Vascular Surgery.
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Deep vein thrombosis (DVT) is a widespread disease with an
incidence of 300:100,000 patients/year. The most impor-
tant early complication is pulmonary embolism. Longterm
complications include the development of a post-throm-
botic syndrome (PTS) in 40e60% of conservatively treated
patients after 10e15 years. Every 10th patient develops
venous ulcers despite subsequent compression therapy.1,2
Venous thrombectomy is a treatment option that may be
considered in selected patients. To avoid re-thrombosis,
venous outflow should be re-established ensuring that there
is no residual stensosis in the iliac veins or inferior vena
cava. Performing intraoperative phlebography, outflow
obstruction such as May-Thurner Syndrome3 can be identi-
fied and treated in a ‘‘one-step procedure’’ by guide-wire
directed thrombectomy or stenting.
This venous hybrid operation has been performed since
1996 at our institution. Good mid-term results were pub-
lished by our group in this journal previosly.4 This study
evaluates the longterm outcome in a consecutive series
with follow-up until 2007. It is to our knowledge the longest
follow-up ever published.
Methods
Study population
Between January 1996 and December 2007, a total of 45
consecutive patients underwent surgery for iliofemoral/
caval thrombosis. 25 patients were treated by endovascular
techniques (balloon-catheter thrombectomy, thrombolysis,
angioplasty, with or without stent deployment) in a one-
step procedure. These patients comprise the study group
reported in this paper. There were 22 female patients,
median age 32 years (range 16e63) and 3 male, median age
61 (56e70) years. 23 thromboses occurred on the left, one
in the right lower limb vessels (cancer-induced phlegmasia
caerulea dolens), and one presented with bilateral throm-
bosis (hypoplasia of the inferior vena cava). Indications for
surgical venous thrombectomy are shown in Table 1.
Thrombectomy only was performed in cases of acute onset
of (<10 days) thrombosis5 although in young patients
treatment was sometimes attempted after longer periods
of venous occlusion. Bed-ridden patients, patients with
a short life expectancy or with underlying malignancy were
excluded from surgical treatment. Graduated elasticTable 1 Indications for surgical venous thrombectomy
(number in this series; modified from reference17).
 Phlegmasia coerulea dolens (nZ 1)
 Iliofemoral thrombosis (nZ 23)
 Thrombosis of the inferior caval vein (nZ 1)
 Acute thrombosis (<10 days) (nZ 22)
 Embolizing thrombus (nZ 2)
 Ascending thrombosis (nZ 0)
 Free-floating thrombus (nZ 0)
 Pregnancy-associated thrombosis (nZ 1)compression stockings with a pressure of 23e32 mmHg and
anticoagulation for at least 6e12 months were recom-
mended for all patients. The duration of oral anti-
coagulation was determined for each patient individually in
cooperation with a medical specialist in thrombophilic
diseases. In most cases the duration of anticoagulation was
in the range 6e12 months.
Aetiology of iliac vein obstructions
Stenosis or obstruction of the common iliac vein was
observed in 88% (22 out of 25) patients. In two patients, the
external iliac vein and in one patient the inferior venous
cava was also affected. In 68% (17 patients), thrombosis
was caused by a spur. One patient presented with a retro-
peritoneal fibrosis three years after surgery and radio-
therapy for curative treatment of a rectal carcinoma.
A compressive obstruction of the common iliac vein was
caused by a prevertebral haematoma after an orthopaedic
operation of the spine. One patient presented with phleg-
masia caerulea dolens caused by local spread of a bladder
tumour. One thrombosis was caused by a metastasising
prostate carcinoma which was diagnosed in the course of
further investigations and one by a congenital hypoplasia of
the inferior vena cava. The three TYPE II patients showed
residual thrombotic narrowing (Table 2).
Classification of venous stenosis
The results of surgical thrombectomy were assessed intra-
operatively by ascending phlebography. We have previously
published our classification of these findings.4 Surgical
thrombectomy clearing all thrombotic material was defined
as TYPE I (nZ 19). Residual thrombotic stenosis after
surgical thrombectomy was referred as TYPE II (nZ 3).
Venous wall obstructions other than residual thrombus (e.g.
May-Thurner syndrome, hypoplasia or extraluminal
compression) were defined as TYPE III (nZ 22) (Fig. 1A).
Residual total venous obstruction of the iliofemoral junc-
tion after thrombectomy were defined as TYPE IV lesions
(nZ 1). Patient classification is summarised in Table 3.
Hybrid procedure
Our operative protocol also has been published before.4 In
brief, patients were operated on under with 15 mmHg
positive end-expiratory pressure (PEEP) ventilation and 30
chest elevation. Transfemoral thrombectomy of the iliac
veins was performed with a wire-guided Fogarty balloon-
catheter under fluoroscopy. Thrombotic material from
below the inguinal ligament was evacuated by manual
compression augmented by wrapping with elastic
bandages. No Fogarty catheter was passed distally from the
femoral vein in order to preserve venous valve function.
Ascending phlebography was routinely performed in all
patients. If residual venous obstruction was detected an
appropriate endovascular treatment was indicated depend-
ing on location,morphology, andnature of the lesion. In TYPE
II lesions, wire-guided thrombectomy alone or in combina-
tion with local thrombolysis was performed using a pulse-
spray catheter (multi-side-hole) with 250,000e500,000 IU
Table 2 Summary of TYPE II and III lesions identified in
our series of 25 patients.
TYPE II patients (nZ 3)
 Obstruction/Stenosis of the common
iliac vein
- Residual thrombotic stenosis nZ 2
 Stenosis of the external iliac vein
- Residual thrombotic stenosis nZ 1
TYPE III patients (nZ 22)
 Obstruction/Stenosis of the common
iliac vein
- Stenosis by spur nZ 17
- Actinic/Radiogenic stenosis nZ 1
- Compressive prevertebral hematoma nZ 1
- Compressive carcinoma (bladder) nZ 1
 Stenosis of the external iliac vein
- Compressive carcinoma (prostate) nZ 1
 Obstruction of the inferior vena cava
- Congenital Hypoplasia nZ 1
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stenting the affected region. Stents were placed using an
introducer sheath guided through the venotomy and posi-
tioned using a guide-wire (Vascutek-Terumo, Glasgow,
Scotland). Both, phlebography and stenting was performed
under guidance of a mobile digital subtraction angiography
unit. When positioning the stent in the common or external
iliac vein carewas taken not to occlude the internal iliac vein
or the contralateral common iliac vein (Fig. 1B). For TYPE I,
no further treatment was necessary. In TYPE IV lesions
treatment was impossible because the occluded vein could
not be passed.
A total of 25 stent-devices were implanted. Of these 52%
were self-expanding [Easy-Wallstent endoprothesis
(nZ 11) (Boston scientific, USA) Symphony stent (nZ 1),
Smart stent (nZ 1) (Cordis, Johnson and Johnson, USA)]Figure 1 22-year-old female who underwent transfemoral thro
a persistent narrowing (May-Thurner Syndrome) of the common ili
deployment of a 16/60 mm Wall-stent (B). A postoperative CT-angio
showed a patent stentgraft (C). Eight years after treatment the
symptoms of post-thrombotic syndrome.and 48% balloon-expanding stents [Palmaz XXL (nZ 11),
Corinthian (nZ 1) (Cordis, Johnson and Johnson, USA)].
Follow-up
Follow-up included recording details of the medical history
(duration of anticoagulation, and compression therapy,
symptoms suggesting thrombotic recurrence and post-
thrombotic symptoms), clinical examination and colour
duplex sonography.
Swelling was assessed by measuring the circumference
of both legs. Skin changes such as reticular or varicose
veins, trophic skin changes and ulceration were docu-
mented. Duplex ultrasonography was performed with
a special focus on patency of stents, patency and compe-
tence of deep and superficial veins, and signs of PTS. The
colour duplex ultrasound system (Xario, Toshiba, Tokyo,
Japan) with equipped with a linear array probe (frequency,
7.5 MHz; range, 5e10 MHz) to investigate the lower limbs
and a phased array probe (frequency, 3.5 MHz; range,
2.25e5 MHz) to investigate the abdomen and pelvis. All
deep and superficial veins in both lower extremities were
examined from the vena cava to the calf veins. The patient
was seated in an upright position with his or her legs
dependent to examine the calf veins. Duplex ultrasonog-
raphy of the thigh and iliac veins was performed with the
patient lying supine. The diagnosis of DVT was based on
both incompressibility of the vein on B-mode and lack of
spontaneous flow on colour duplex imaging. Venous reflux
was defined as the presence of reverse blood flow greater
than 0.5 seconds following the release of a firm manual calf
or thigh compression.6 Patients were categorized according
to the CEAP classification.7 In addition the ‘‘Venous Clinical
Severity Scoring’’ (VCSS) for longitudinal studies was used.8
Statistical analysis
Data were collected in an Excel database (Excel Microsoft
Corporation, Redmond, WA, USA). Data consistency checksmbectomy with subsequent ascending venography. It shows
ac vein (TYPE III thrombectomy) (A) which was treated by the
graphy (sagittal reconstruction with center-line measurement)
reconstruction was still patent and the patient showed no
Table 3 Classification of phlebographic findings after
venous thrombectomy (modified4).
 TYPE I complete restoration of venous inflow
 TYPE II residual stenosis due to remaining thrombus
 TYPE III residual stenosis due to other reasons than
thrombus
(e.g. May-Thurner Syndrome,
extrinsic compression)
 TYPE IV complete obstruction
Table 5 Thrombophilic disorders were found in 9 patients
(Five patients had more than one risk factor).
 Factor-V-Leiden (nZ 5)
 Protein S deficiency (nZ 1)
 Protein C deficiency (nZ 1)
 Prothrombin mutation (nZ 3)
 PAI-gene mutation (nZ 4)
 Elevated factor VIII activity (nZ 1)
 Hyperhomocysteinaemia (nZ 1)
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mistakes, patient charts were reviewed to minimise
incomplete data sets. For continuous variables, means and
standard deviations were calculated. Wilcoxon signed-rank
test was used for statistical analysis of VCSS. Patency rates
and actuarial re-thrombosis were estimated by Kaplan-
Meier life table analysis using XLstat (Addinsoft, New York,
USA). A p-value <0.05 was defined statistically significant.
Results
Follow-up
During follow-up three male patients died (all TYPE III) due
to cancer. Two TYPE II patients and one TYPE III patient
were lost to follow-up. Therefore 19 of 25 patients (one
TYPE II and 18 TYPE III patients) were examined. The
median follow-up of all patients examined was 68 months
(range 3e129 months).
Duplex ultrasonography revealed that 14 of 19 patients
had no abnormal findings in any part of the venous system.
Two stents were permanently occluded. In one stent the
thrombosis partially recanalised spontaneously within two
years of the operation. We could find no evidence of
progressive stenosis in the patent stents during the follow-
up period.
Incompetence of the common femoral vein was found in
one patient and in four cases the great saphenous vein was
incompetent.
Risk factors and thrombophilic disorders
In addition to anatomical obstruction all patients had risk
factors for thrombosis (table 4). 50% of patients had more
than one (up to three) risk factors. Nine patients had
thrombophilic disorders, and five patients had more thanTable 4 Risk factors for thrombosis in this series (50% had
more than one risk factor).
 Operation (nZ 4)
 Immobilisation other than
operation
(nZ 3)
 Gravidity/postpartum (nZ 3)
 Metastasising Carcinoma (nZ 2)
 Oral contraceptives (nZ 9)
 Thrombophilic disorders (nZ 9)one thrombophilia. Except for one homozygous PAI (plas-
minogenactivator-inhibitor 1)-gene mutation all the other
gene mutations were heterozygous (Table 5).
Feasibility and clinical outcome
Technical feasibility of the surgical thrombectomy proce-
dure was 100% (25/25) from which the operative mortality
was 0%. Endovascular reconstruction was accomplished
with one complication. One stent (Palmaz XXL) was dis-
lodged into the inferior vena cava by the introducer sheath
during deployment of a second stent and was corrected by
retraction and repositioning with a balloon-catheter.
Procedure-related pulmonary embolism was not studied by
CT scanning since no patient showed any clinical sign of
pulmonary embolism.
Early re-thrombosis in the first seven days after opera-
tion occurred in five TYPE III patients. In three a spur was
undiagnosed initially (two patients underwent stening and
patient one refused a second operation). One re-throm-
bectomy was not successful (the re-thrombosis was diag-
nosed 10 days after the initial thrombectomy), but the
thrombosis partially recanalised spontaneously within two
years. One re-thrombosis occurred due to post-thrombotic
lesions in the venous system due to residual wall roughness.
In this setting, prospects of success by another operation
seemed poor and therefore conservative treatment was
preferred.
In summary, two of five re-thromboses were successfully
recanalised by a second operation and there was no late
re-thrombosis.
Four patients reported minor symptoms including
telangiectases, swelling or varicosities. No ulcer occurred.
The CEAP clinical stage is shown in Table 6. The VCSS
showed a decrease in all patients but one (pZ 0.0001) in
the course of the follow-up. The median of the VCSSTable 6 CEAP clinical stage.
C0a: nZ 11 (no symptoms)
C1a: nZ 3 (asymptomatic telangiectases
and reticular veins)
C2a: nZ 1 (asymptomatic varicosities)
C3s: nZ 1 (symptomatic edema)
C1, 2s: nZ 2 (symptomatic telangiectases
and reticular veins and varicosis)
C2, 3s: nZ 1 (symptomatic varicosities and
edema)
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Figure 2 Kaplan-Meier estimates of primary patency rate
after venous thrombectomy.
Longterm Results After Surgical Thrombectomy 353decreased from 6 points preoperatively to 0. In one patient
the score increased from 6 to 7 points.
During a median follow-up of 68 months the primary and
secondary patency rates of the endovascular reconstruction
were 74% (nZ 14 of 19) and 84% (nZ 16 of 19), respec-
tively (Figs. 1C, 2 and 3).
Discussion
In this study we found that venous thrombectomy with
simultaneous stenting shows excellent longterm results in
selected patients with symptomatic iliofemoral venous
thrombosis.
In recent decades surgical treatment of deep vein
thrombosis (DVT) was rarely been mentioned. Haller and
Lansing described venous thrombectomy in the 1960s with
excellent early results.9,10 However, the follow-up results
showed high rates of re-thrombosis probably due to
a flawed study design and a lack of intraoperative phlebo-
graphy. With intraoperative phlebography anatomical
obstruction of the iliac veins such as May-Thurner SyndromSecondary Patency Rate
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Figure 3 Kaplan-Meier estimates of secondary patency rate
after venous thrombectomy.can be easily detected. Current literature provides much
more encouraging results with patency rates after endo-
vascular treatment of 70% and more.5,11e13
However, in the current guidelines of the ‘‘American
Heart association’’ (AHA) for treatment of venous throm-
boembolism operative treatment of iliofemoral venous
thromboembolism is only recommended in impending acute
limb loss. On the other hand, the American College of Chest
Physicians (ACCP) guidelines advise operative venous
thrombectomy in selected patients with acute iliofemoral
DVT to reduce acute symptoms and post-thrombotic
morbidity if appropriate expertise and resources are
available.14
In the study presented here, the clinical outcome during
the follow-up period was excellent, although we acknowl-
edge that this is based on limited numbers. Only four
patients suffered from minor signs of post-thrombotic
syndrome in our series. One patient increased in the VCSS
because she wore compression stockings permanently. The
intensity of her pain diminished. This fits with the majority
of recent surgical studies.5,11,12,15e20 The accepted method
of treating DVT is the use of heparin in combination with
compression therapy. These measures are effective at
preventing acute complications such as ascending DVT or
pulmonary embolism. Late sequelae, such as PTS, can be
reduced by wearing compression stockings,21 but despite
this up to 60% of all conservatively treated DVT-patients
develop a PTS, every 10th patient suffers venous leg
ulceration.1,2
There is evidence that early thrombectomy can prevent
longterm venous damage and PTS. See-Tho et al. showed
that inflammatory changes that lead to venous valve
destruction are reversible if the thrombus dissolves early.22
Caps et al. previously described that the proximal throm-
botic occlusion remaining in human leg veins will lead to
progressive distal valvular incompetence.23
Although surgical thrombectomy is an invasive treat-
ment it is associated with a low rate of peri- and post-
procedural risk compared to the alternative ‘‘less invasive’’
approaches. Catheter-directed thrombolysis results in
a mean infusion time of w53 h and major bleeding
complications of 11% have been described.1 Catheter-
directed thrombolysis plus mechanical thrombectomy has
mean infusion times of w23 h and major bleeding compli-
cations of 14%.24 Systemic fibrinolysis should be used with
great caution due to the high rate of complication associ-
ated with this treatment.25
Groin lymphatic fistulas are a troublesome finding after
surgery. Local morbidity was low in this study and in
international literature (1%).26e28 Local complications
included one lymphatic fistula and one seroma. Both were
treated conservatively.
Creation of arteriovenous fistulas (AVF) after throm-
bectomy17e19 or stent deployment5,11,12 is proposed by
some authors. Both methods are effective and show good
longterm results. Some even advise a combination of both
techniques.29 In our opinion, AVF is only indicated in
ascending thrombosis but not necessary in descending
thrombosis if any stenosis is completely removed. A disad-
vantage of AVF is an obligatory second operation after w6
weeks.29 A long-standing AVF can lead to distal common
femoral vein stenosis.30
354 P. Ho¨lper et al.Venous stenoses are prone to elastic recoil after balloon
dilatation, so stent placement considerably improves
patency.5 We observed good stent patency rates in our
study and similar findings have been reported in other
larger clinical series.5,11e13
Re-thrombosis in our patients only occurred if stenosis
was not treated adequately at the initial operation. This is
in line with findings of a multi-centre registry of 473
patients who were treated with catheter-directed throm-
bolysis without further reconstruction. A one-year primary
patency rate of 79% could only be achieved if no residual
stenosis was persistent. Residual stenosis of 1e50% had
a one-year patency rate of only 58% and residual stenosis of
more than 50% of only 32%.1 If a residual stenosis occurred
after catheter-directed thrombolysis stent deployment led
to patency rates over 80%.31 Mickley et al. had rates of
re-thrombosis of 73% if a spur was not treated, 13% after
treatment and 6% in patients without any stenosis.11
As in our series, re-thrombosis only occurred in thefirst few
days after thrombectomy.5,11,12,17e19 This was mainly due to
missed residual stenoses (mainly spurs) or in some cases
because of acute thrombosis of post-thrombotic lesions.
Surgical thrombectomy is not appropriate in such cases.
Some authors describe good results after treatment of
chronic symptomatic stenosis and occlusion with angio-
plasty and stent deployment. Juhan et al. described
a primary and secondary patency rate of 88% and 100% after
22 months, respectivly.5
Negle´n et al. treated 447 patients with stenosis and
stenosis plus reflux affected by chronic venous insufficiency
(swelling, pain, venous claudication, ulcers). By treating
the venous outflow with angioplasty and stent deployment
50% were completely relieved of pain, 33% were relieved of
swelling and 55% of ulcerated limbs healed.12
Conclusion
This study shows that residual stenoses of the iliac veins
after venous thrombectomy can be reconstructed in a one-
stage venous hybrid operation with excellent longterm
patency and resolution of clinical symptoms in selected
patients with symptomatic iliofemoral venous thrombosis.Conflict of Interest/Funding
None.
References
1 Mewissen MW, Seabrook GR, Meissner MH, Cynamon J,
Labropoulos N, Haughton SH. Catheterdirected thrombolysis for
lower extremity deep venous thrombosis: report of a national
multicenter registry. Radiology 1999;211:39e49.
2 Diehm C, Stammler F, Amendt K. Die tiefe venenthrombose e
diagnostik und therapie. Dt A¨rztebl 1997;94:A-301e11.
3 May R, Thurner J. Z Kreislaufforschung 1956;45:912e22.
4 Schwarzbach MHM, Schumacher H, Bo¨ckler D, Fu¨rstenberger S,
Thomas F, Seelos R, et al. Surgical thrombectomy followed by
intraoperative endovascular reconstruction for symptomatic
iliofemoral venous thrombosis. Eur J Vasc Endovasc Surg 2005;
29:58e66.5 Juhan C, Hartung O, Alimi Y, Barthe´lemy P, Valerio N, Portier F.
Treatment of nonmalignent obstructive iliocavl lesions by stent
placement: mid-term results. Ann Vasc Surg 2001;15:227e32.
6 Labropoulos N, Trongson J, Pryor L, Tassiopoulos AK, Kang SS,
Ashraf Mansour M, et al. Definition of venous reflux in lower-
extremity veins. J Vasc Surg 2003;38:793e8.
7 Eklo¨f B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P,
Wakefield TW, et al. American Venous Forum International Ad
Hoc Committee for Revision of the CEAP Classification. Revision
of the CEAP classification for chronic venous disorders:
consensus statement. J Vasc Surg 2004;40:1248e52 [Review].
8 Rutherford RB, Padberg FT, Comerota AJ, Kistner RL,
Meissner MH, Moneta GL. Venous severity scoring: an adjunct to
venous outcome assessment. J Vasc Surg 2000;31:1307e12.
9 Haller Jr JA, Abrams BL. Use of thrombectomy in the treatment
of acute iliofemoral venous thrombosis in forty-five patients.
Ann Surg 1963;158:561e9.
10 Lansing AM, Davis WM. Five-year follow-up study of iliofemoral
venous thrombectomy. Ann Surg 1968;168:620e8.
11 Mickley V, Schwagierek R, Rilinger N, Go¨rich J, Sunder-
Plassmann L. Left iliacvenous thrombosis caused by venous
spur: treatment with thrombectomy and stent implantation.
J Vasc Surg 1998;28:492e7.
12 Negle´n P, Thrasher TL, Raju S. Venous outflow obstruction: an
underestimated contributor to chronic venous disease. J Vasc
Surg 2003;38:879e85.
13 Mussa FF, Peden EK, Zhou W, Lin PH, Lumsden AB, Bush RL. Iliac
vein stenting for chronic venous insufficiency. Tex Heart Inst J
2007;34:60e6.
14 Hirsh J, Guyatt G, Albers GW, Harrington R, Schu¨nemann HJ.
American College of Chest Physicians evidence-based clinical
practice guidelines (8th edition). Chest 2008;133:71Se105S.
15 Bla¨ttler W, Bla¨ttler IK. Relief of obstructive pelvic venous symp-
toms with endoluminal stenting. J Vasc Surg 1999;29:484e8.
16 Neglen P, Raju S. Baloon dilation and stenting of chronic iliac
vein obstruction: technical aspects and early clinical outcome.
J Endovasc Ther 2000;7:79e91.
17 Plate G, Eklof B, Norgren L, Ohlin P, Dahlstro¨m JA. Venous
thrombectomy for iliofemoral vein thrombosis e 10-year results
of a prospective randomised study. Eur J Vasc Endovasc Surg
1997;4:367e74.
18 Pillny M, Sandmann W, Luther B, Mu¨ller BT, Tutschek B,
Scharf RE, et al. Deep venous thrombosis during pregnancy
and after delivery: indications for and results of thrombec-
tomy. J Vasc Surg 2003;37:528e32.
19 Juhan MC, Alimi YS, Barthelemy PJ, Fabre DF, Riviere CD. Late
results of iliofemoral venous thrombectomy. J Vasc Surg 1997;
25:417e22.
20 Comerota AJ, Paolini D. Treatment of acute iliofemoral deep
venous thrombosis: a strategy of thrombus removal. Eur J Vasc
Endovasc Surg 2007;33:351e60 [Review].
21 Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A,
Bernardi E, et al. Below-knee elastic compression stockings to
prevent the post-thrombotic syndrome: a randomized,
controlled trial. Ann Intern Med 2004;141:249e56.
22 See-Tho K, Harris Jr EJ. Thrombosis with outflow obstruction
delays thrombolysis and results in chronic wall thickening of rat
veins. J Vasc Surg 1998;28:115e22.
23 Caps MT, Meissner MH, Tullis MJ, Polissar NL, Manzo RA,
Strandness Jr DE, et al. Venous thrombus stability during acute
phase of therapy. Vasc Med 1999;4:9e14.
24 VedanthamS, Vesely TM, Parti N, DarcyM,HovsepianDM, PicusD.
Lower extremity venous thrombolysis with adjunctive mechan-
ical thrombectomy. J Vasc Interv Radiol 2002;13:1001e8.
25 Pillny M, Luther B, Mu¨ller BT, Sandmann W. Enquiries concern-
ing the therapy for deep venous thrombosis to the members of
the German Society for Vascular Surgery e 1999. Chirurg 2002;
73:180e4.
Longterm Results After Surgical Thrombectomy 35526 Slappy AL, Hakaim AG, Oldenburg WA, Paz-Fumagalli R,
McKinney JM. Femoral incision morbidity following endovascular
aortic aneurysmrepair. J Vasc Endovascular Surg2003;37:105e9.
27 Tyndall SH, Shepard AD, Wilczewski JM, Reddy DJ, Elliott Jr JP,
Ernst CB. Groin lymphatic complications after arterial recon-
struction. J Vasc Surg 1994;19:858e63 [discussion 863e864].
28 Miller GV, Lewis WG, Sainsbury JR, Macdonald RC. Morbidity of
varicose vein surgery: auditing the benefit of changing clinical
practice. Ann R Coll Surg Engl 1996;78:345e9.29 Hartung O, Benmiloud F, Barthelemy P, Dubuc M, Boufi M,
Alimi YS. Late results of surgical venous thrombectomy with
iliocaval stenting. J Vasc Surg 2008;47:381e7.
30 Wohlgemuth WA, Weber H, Loeprecht H, Tietze W, Bohndorf K.
PTA and stenting of benign venous stenoses in the pelvis: long-
term results. Cardiovasc Intervent Radiol 2000;23:9e16.
31 Comerota A, Aldridge SC. Thrombolytic therapy for deep
venous thrombosis: a clinical review. Can J Surg 1993;36:
359e64.
